335 related articles for article (PubMed ID: 38520539)
1. Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes.
Rendic SP; Guengerich FP
Arch Toxicol; 2024 Jun; 98(6):1581-1628. PubMed ID: 38520539
[TBL] [Abstract][Full Text] [Related]
2. Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.
Rendic SP; Guengerich FP
Arch Toxicol; 2021 Feb; 95(2):395-472. PubMed ID: 33459808
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
4. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
5. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
Rendic SP
Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
[TBL] [Abstract][Full Text] [Related]
6. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
Shimada T; Yamazaki H; Mimura M; Inui Y; Guengerich FP
J Pharmacol Exp Ther; 1994 Jul; 270(1):414-23. PubMed ID: 8035341
[TBL] [Abstract][Full Text] [Related]
7. A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes.
Grothusen A; Hardt J; Bräutigam L; Lang D; Böcker R
Arch Toxicol; 1996; 71(1-2):64-71. PubMed ID: 9010587
[TBL] [Abstract][Full Text] [Related]
8. Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes.
Kim SY; Suzuki N; Santosh Laxmi YR; Rieger R; Shibutani S
Chem Res Toxicol; 2003 Sep; 16(9):1138-44. PubMed ID: 12971802
[TBL] [Abstract][Full Text] [Related]
9. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
Knights KM; Rowland A; Miners JO
Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865
[TBL] [Abstract][Full Text] [Related]
10. Drug-metabolizing enzymes: mechanisms and functions.
Sheweita SA
Curr Drug Metab; 2000 Sep; 1(2):107-32. PubMed ID: 11465078
[TBL] [Abstract][Full Text] [Related]
11. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes.
Yamazaki H; Shaw PM; Guengerich FP; Shimada T
Chem Res Toxicol; 1998 Jun; 11(6):659-65. PubMed ID: 9625734
[TBL] [Abstract][Full Text] [Related]
12. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 and flavin-containing monooxygenase enzymes are responsible for differential oxidation of the anti-thyroid-cancer drug vandetanib by human and rat hepatic microsomal systems.
Indra R; Pompach P; Vavrová K; Jáklová K; Heger Z; Adam V; Eckschlager T; Kopečková K; Arlt VM; Stiborová M
Environ Toxicol Pharmacol; 2020 Feb; 74():103310. PubMed ID: 31837525
[TBL] [Abstract][Full Text] [Related]
14. Intraindividual Variation and Correlation of Cytochrome P450 Activities in Human Liver Microsomes.
Fang Y; Gao J; Wang T; Tian X; Gao N; Zhou J; Zhang HF; Wen Q; Jin H; Xing YR; Qiao HL
Mol Pharm; 2018 Nov; 15(11):5312-5318. PubMed ID: 30346185
[TBL] [Abstract][Full Text] [Related]
15. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
16. Oxidation of benzo[a]pyrene by recombinant human cytochrome P450 enzymes.
Bauer E; Guo Z; Ueng YF; Bell LC; Zeldin D; Guengerich FP
Chem Res Toxicol; 1995; 8(1):136-42. PubMed ID: 7703357
[TBL] [Abstract][Full Text] [Related]
17. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs.
Mancy A; Antignac M; Minoletti C; Dijols S; Mouries V; Duong NT; Battioni P; Dansette PM; Mansuy D
Biochemistry; 1999 Oct; 38(43):14264-70. PubMed ID: 10572000
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.
Gelboin HV; Krausz K
J Clin Pharmacol; 2006 Mar; 46(3):353-72. PubMed ID: 16490812
[TBL] [Abstract][Full Text] [Related]
19. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
20. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals.
Rendic S; Guengerich FP
Chem Res Toxicol; 2015 Jan; 28(1):38-42. PubMed ID: 25485457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
